{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T10:02:48Z","timestamp":1767952968022,"version":"3.49.0"},"reference-count":28,"publisher":"Termedia Sp. z.o.o.","issue":"3","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cent Eur J Immunol"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The aim of the study was to compare the first year of disease in children with idiopathic nephrotic syndrome (INS) treated according to two prednisone dosing regimens: a\u00a0weight-based schedule (2 mg\/kg\/24 h in the 1st month, 2 mg\/kg\/48 h in the 2nd month, with dose tapering during the following 4 months), and a\u00a0body surface area (BSA)-based schedule (60 mg\/m&lt;sup&gt;2&lt;\/sup&gt;\/24 h in the 1st month, 40 mg\/m&lt;sup&gt;2&lt;\/sup&gt;\/48 h in the 2nd month, with dose tapering during the following 4 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>In 2 groups of children treated with weight- and BSA-based regimens (20 patients, 3.13 \u00b11.01 years, treated in 2010-2013 and 20 patients, 5.13 \u00b12.86 years, treated in 2014-2016) clinical and anthropometrical parameters, number of INS relapses, total prednisone dose (mg\/kg\/year), and steroid adverse effects were compared during the first year of disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Children treated with the weight-based steroid regimen received a\u00a0higher total annual prednisone dose (259.06 \u00b179.54 vs. 185.83 \u00b172.67 mg\/kg\/24 h, p = 0.004) and had a\u00a0shorter (though not significantly) period without prednisone (38.25 \u00b155.83 vs. 75.90 \u00b173.06 days, p = 0.062) compared to patients treated with the BSA-based regimen. There was no difference in number of relapses between groups (2.20 \u00b11.64 vs. 1.60 \u00b11.67, p = 0.190) but more patients relapsed in the weight-based group (19\/20 vs. 13\/20, p = 0.044). No differences in Z-score values of height, weight, and body mass index (BMI) were observed. No steroid-related adverse events were noted except for arterial hypertension (4\/20 vs. 5\/20 patients, p = 1.000).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The BSA-based regimen of prednisone dosing in children with INS reduces exposure to steroids and risk of relapse, as well as increases days off steroids in the first year compared to the weight-based regimen with a\u00a0high second-month dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5114\/ceji.2021.109720","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T06:20:01Z","timestamp":1634019601000},"page":"344-350","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of idiopathic nephrotic syndrome with two steroid dosing regimens \u2013 one-year observational study"],"prefix":"10.5114","volume":"46","author":[{"given":"Ma\u0142gorzata","family":"Pa\u0144czyk-Tomaszewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Skrzypczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kacper","family":"Mroczkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Leszczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Mizerska-Wasiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"ref-1540368","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1001\/jama.1957.02980320028008","article-title":"The nephrotic syndrome; clinical observations on therapy with prednisone and other steroids","volume":"165","author":"Goodman HC","year":"1957","unstructured":"Goodman HC, Baxter JH (1957): The nephrotic syndrome; clinical observations on therapy with prednisone and other steroids. J Am Med Assoc 165: 1798-1808.","journal-title":"J Am Med Assoc"},{"key":"ref-1540369","first-page":"139","article-title":"KDIGO Clinical practice guideline for glomerulonephritis","volume":"2","author":"KDIGO","year":"2012","unstructured":"KDIGO (2012): KDIGO Clinical practice guideline for glomerulonephritis. Kidney Int Suppl (2012) 2: 139-274.","journal-title":"Kidney Int Suppl (2012)"},{"key":"ref-1540370","first-page":"Cd001533","article-title":"Corticosteroid therapy for nephrotic syndrome in children","volume":"2015","author":"Hahn D","year":"2015","unstructured":"Hahn D, Hodson EM, Willis NS, et al. (2015): Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2015: Cd001533.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref-1540371","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ki.2014.240","article-title":"Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome","volume":"87","author":"Sinha A","year":"2015","unstructured":"Sinha A, Saha A, Kumar M, et al. (2015): Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int 87: 217-224.","journal-title":"Kidney Int"},{"key":"ref-1540372","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ki.2014.260","article-title":"A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment","volume":"87","author":"Yoshikawa N","year":"2015","unstructured":"Yoshikawa N, Nakanishi K, Sako M, et al. (2015): A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 87: 225-232.","journal-title":"Kidney Int"},{"key":"ref-1540373","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23260","article-title":"Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT","volume":"23","author":"Webb NJ","year":"2019","unstructured":"Webb NJ, Woolley RL, Lambe T, et al. (2019): Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT. Health Technol Assess 23: 1-108.","journal-title":"Health Technol Assess"},{"key":"ref-1540374","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13052-017-0356-x","article-title":"The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I-Diagnosis and treatment of the first episode and the first relapse","volume":"43","author":"Pasini A","year":"2017","unstructured":"Pasini A, Benetti E, Conti G, et al. (2017): The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I-Diagnosis and treatment of the first episode and the first relapse. Ital J Pediatr 43: 41.","journal-title":"Ital J Pediatr"},{"key":"ref-1540375","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.kint.2020.07.045","article-title":"Management of idiopathic childhood nephrotic syndrome in sub-Saharan Africa: Ibadan consensus statement","volume":"99","author":"Esezobor C","year":"2021","unstructured":"Esezobor C, Ademola AD, Adetunji AE, et al. (2021): Management of idiopathic childhood nephrotic syndrome in sub-Saharan Africa: Ibadan consensus statement. Kidney Int 99: 59-67.","journal-title":"Kidney Int"},{"key":"ref-1540376","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ki.1978.23","article-title":"Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children","volume":"13","author":"ISKDC","year":"1978","unstructured":"ISKDC (1978): Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 13: 159-165.","journal-title":"Kidney Int"},{"key":"ref-1540377","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00467-008-1089-2","article-title":"Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent?","volume":"24","author":"Feber J","year":"2009","unstructured":"Feber J, Al-Matrafi J, Farhadi E, et al. (2009): Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? Pediatr Nephrol 24: 1027-1031.","journal-title":"Pediatr Nephrol"},{"key":"ref-1540378","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s00467-011-1961-3","article-title":"Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference?","volume":"26","author":"Saadeh SA","year":"2011","unstructured":"Saadeh SA, Baracco R, Jain A, et al. (2011): Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference? Pediatr Nephrol 26: 2167-2171.","journal-title":"Pediatr Nephrol"},{"key":"ref-1540379","first-page":"238","article-title":"Recommendations of Polish Society Paediatric Nephrology for the management of the child with nephrotic syndrome","volume":"8","author":"Zi\u00f3\u0142kowska H","year":"2015","unstructured":"Zi\u00f3\u0142kowska H, Grenda R, Musia\u0142 K, et al. (2015): Recommendations of Polish Society Paediatric Nephrology for the management of the child with nephrotic syndrome. Forum Nefrologiczne 8: 238-256.","journal-title":"Forum Nefrologiczne"},{"key":"ref-1540380","first-page":"18","article-title":"Indicators of the somatic development of Warsaw children and the young","volume":"2","author":"Palczewska I","year":"2001","unstructured":"Palczewska I, Nied\u017awiecka Z (2001): Indicators of the somatic development of Warsaw children and the young. Med Development Age 2: 18-118.","journal-title":"Med Development Age"},{"key":"ref-1540381","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0272-6386(03)00346-9","article-title":"A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children","volume":"41","author":"Hiraoka M","year":"2003","unstructured":"Hiraoka M, Tsukahara H, Matsubara K, et al. (2003): A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 41: 1155-1162.","journal-title":"Am J Kidney Dis"},{"key":"ref-1540382","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00467-015-3285-1","article-title":"Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial","volume":"31","author":"Raman V","year":"2016","unstructured":"Raman V, Krishnamurthy S, Harichandrakumar KT (2016): Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial. Pediatr Nephrol 31: 595-604.","journal-title":"Pediatr Nephrol"},{"key":"ref-1540383","first-page":"203","article-title":"Management of steroid sensitive nephrotic syndrome: revised guidelines","volume":"45","author":"Bagga A","year":"2008","unstructured":"Bagga A, Ali U, Banerjee S, et al. (2008): Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr 45: 203-214.","journal-title":"Indian Pediatr"},{"key":"ref-1540384","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s004670050708","article-title":"Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome","volume":"13","author":"Bagga A","year":"1999","unstructured":"Bagga A, Hari P, Srivastava RN (1999): Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol 13: 824-827.","journal-title":"Pediatr Nephrol"},{"key":"ref-1540385","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1651-2227.1995.tb13787.x","article-title":"Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children","volume":"84","author":"Ksiazek J","year":"1995","unstructured":"Ksiazek J, Wyszy\u0144ska T (1995): Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr 84: 889-893.","journal-title":"Acta Paediatr"},{"key":"ref-1540386","doi-asserted-by":"crossref","first-page":"105490","DOI":"10.1016\/j.jsbmb.2019.105490","article-title":"The impact of steroids on the injured podocytes in nephrotic syndrome","volume":"196","author":"Hosseiniyan Khatibi SM","year":"2020","unstructured":"Hosseiniyan Khatibi SM, Ardalan M, Abediazar S, et al. (2020): The impact of steroids on the injured podocytes in nephrotic syndrome. J Steroid Biochem Mol Biol 196: 105490.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref-1540387","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00467-018-3929-z","article-title":"Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome","volume":"34","author":"Schijvens AM","year":"2019","unstructured":"Schijvens AM, Ter Heine R, de Wildt SN, et al. (2019): Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatr Nephrol 34: 389-403.","journal-title":"Pediatr Nephrol"},{"key":"ref-1540388","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1681\/ASN.2005020142","article-title":"Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins","volume":"16","author":"Wada T","year":"2005","unstructured":"Wada T, Pippin JW, Marshall CB, et al. (2005): Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol 16: 2615-2625.","journal-title":"J Am Soc Nephrol"},{"key":"ref-1540389","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.ki.5001655","article-title":"Direct effects of dexamethasone on human podocytes","volume":"70","author":"Xing CY","year":"2006","unstructured":"Xing CY, Saleem MA, Coward RJ, et al. (2006): Direct effects of dexamethasone on human podocytes. Kidney Int 70: 1038-1045.","journal-title":"Kidney Int"},{"key":"ref-1540390","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00467-011-1993-8","article-title":"Dosing of glucocorticosteroids in nephrotic syndrome","volume":"26","author":"Mehls O","year":"2011","unstructured":"Mehls O, Hoyer PF (2011): Dosing of glucocorticosteroids in nephrotic syndrome. Pediatr Nephrol 26: 2095-2098.","journal-title":"Pediatr Nephrol"},{"key":"ref-1540391","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s10157-020-01875-y","article-title":"Efficacy of body weight vs body surface area-based prednisolone regimen in nephrotic syndrome","volume":"24","author":"Basu B","year":"2020","unstructured":"Basu B, Bhattacharyya S, Barua S, et al. (2020): Efficacy of body weight vs body surface area-based prednisolone regimen in nephrotic syndrome. Clin Exp Nephrol 24: 622-629.","journal-title":"Clin Exp Nephrol"},{"key":"ref-1540392","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00467-018-4127-8","article-title":"Equations to estimate prednisone dose using body weight","volume":"34","author":"Emma F","year":"2019","unstructured":"Emma F, Montini G,Gargiulo A (2019): Equations to estimate prednisone dose using body weight. Pediatr Nephrol 34: 685-688.","journal-title":"Pediatr Nephrol"},{"key":"ref-1540393","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2013.12.002","article-title":"Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children","volume":"63","author":"Samuel S","year":"2014","unstructured":"Samuel S, Bitzan M, Zappitelli M, et al. (2014): Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children. Am J Kidney Dis 63: 354-362.","journal-title":"Am J Kidney Dis"},{"key":"ref-1540394","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jped.2018.07.014","article-title":"Effect of prednisolone on linear growth in children with nephrotic syndrome","volume":"96","author":"Valavi E","year":"2020","unstructured":"Valavi E, Aminzadeh M, Amouri P, et al. (2020): Effect of prednisolone on linear growth in children with nephrotic syndrome. J Pediatr (Rio J) 96: 117-124.","journal-title":"J Pediatr (Rio J)"},{"key":"ref-1540395","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/ajcn\/80.5.1334","article-title":"Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids","volume":"80","author":"Foster BJ","year":"2004","unstructured":"Foster BJ, Shults J, Zemel BS, et al. (2004): Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids. Am J Clin Nutr 80: 1334-1341.","journal-title":"Am J Clin Nutr"}],"container-title":["Central European Journal of Immunology"],"original-title":[],"link":[{"URL":"https:\/\/ceji.termedia.pl\/pdf-138154-129692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ceji.termedia.pl\/pdf-138154-129692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:33:03Z","timestamp":1767947583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ceji.termedia.pl\/Treatment-of-idiopathic-nephrotic-syndrome-with-two-steroid-dosing-regimens-one-year,138154,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"alternative-id":["138154"],"URL":"https:\/\/doi.org\/10.5114\/ceji.2021.109720","relation":{},"ISSN":["1426-3912","1644-4124"],"issn-type":[{"value":"1426-3912","type":"print"},{"value":"1644-4124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]}}}